Profile data is unavailable for this security.
About the company
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. OGSIVEO (nirogacestat) is the Company's Food and Drug Administration (FDA)-approved therapy. OGSIVEO (nirogacestat) is approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The Company also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. Its ongoing developments include Nirogacestat for treatment of ovarian granulosa cell tumors, Nirogacestat in combination with B-cell maturation antigen (BCMA)-targeted agents, Mirdametinib Phase 2b ReNeu trial in NF1-PN and Brimarafenib (BGB-3245). The Company's early-stage pipeline includes SW-682, an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluated in Hippo-mutant solid tumors.
- Revenue in USD (TTM)86.19m
- Net income in USD-301.06m
- Incorporated2019
- Employees305.00
- LocationSpringWorks Therapeutics Inc100 Washington BlvdSTAMFORD 06902-9302United StatesUSA
- Phone+1 (203) 883-9490
- Fax+1 (302) 655-5049
- Websitehttps://www.springworkstx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vera Therapeutics Inc | 0.00 | -107.85m | 2.24bn | 72.00 | -- | 6.83 | -- | -- | -2.20 | -2.20 | 0.00 | 5.98 | 0.00 | -- | -- | 0.00 | -36.41 | -- | -39.42 | -- | -- | -- | -- | -- | -- | -- | 0.1329 | -- | -- | -- | -7.79 | -- | -- | -- |
Keros Therapeutics Inc | 271.00k | -168.05m | 2.29bn | 149.00 | -- | 5.23 | -- | 8,432.09 | -5.13 | -5.13 | 0.0082 | 11.64 | 0.0007 | -- | -- | 1,992.65 | -41.43 | -35.95 | -43.43 | -38.07 | -- | -- | -62,012.55 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
Arrowhead Pharmaceuticals Inc | 19.65m | -538.64m | 2.34bn | 525.00 | -- | 7.07 | -- | 119.08 | -4.65 | -4.65 | 0.1701 | 2.66 | 0.0234 | -- | -- | 37,424.76 | -65.18 | -20.02 | -73.62 | -24.65 | -- | -- | -2,785.85 | -61.79 | -- | -154.93 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
Janux Therapeutics Inc | 15.13m | -44.05m | 2.35bn | 64.00 | -- | 3.57 | -- | 155.25 | -0.9152 | -0.9152 | 0.3088 | 12.61 | 0.0293 | -- | -- | 236,359.40 | -8.53 | -- | -8.78 | -- | -- | -- | -291.17 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
Agios Pharmaceuticals Inc | 31.31m | -364.93m | 2.35bn | 383.00 | -- | 3.56 | -- | 75.10 | -6.49 | -6.49 | 0.5568 | 11.61 | 0.0337 | 0.1687 | 10.41 | 81,738.91 | -39.28 | -29.54 | -41.94 | -31.88 | 89.33 | -- | -1,165.69 | -3,826.10 | 9.71 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
Azenta Inc | 658.62m | -156.38m | 2.36bn | 3.30k | -- | 1.22 | -- | 3.59 | -2.82 | -2.81 | 11.73 | 39.50 | 0.2443 | 3.08 | 3.49 | 188,176.30 | -5.80 | -0.5934 | -6.27 | -0.6725 | 39.78 | 43.08 | -23.74 | -2.17 | 4.21 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
Neumora Therapeutics Inc | 0.00 | -274.18m | 2.36bn | 108.00 | -- | 6.19 | -- | -- | -1.66 | -1.66 | 0.00 | 2.38 | 0.00 | -- | -- | 0.00 | -71.73 | -- | -76.67 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
Immunitybio Inc | 1.31m | -597.65m | 2.39bn | 622.00 | -- | -- | -- | 1,826.54 | -0.9356 | -0.9356 | 0.0021 | -1.01 | 0.0036 | -- | 0.49 | 2,082.80 | -162.54 | -112.76 | -1,927.61 | -316.07 | -- | -- | -45,701.07 | -37,700.74 | 3.88 | -2.33 | 3.69 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
SpringWorks Therapeutics Inc | 86.19m | -301.06m | 2.42bn | 305.00 | -- | 4.35 | -- | 28.13 | -4.44 | -4.44 | 1.25 | 7.50 | 0.1519 | -- | -- | 282,577.10 | -53.07 | -36.97 | -57.99 | -39.49 | 95.27 | -- | -349.32 | -2,176.46 | 7.77 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
CG Oncology Inc | 650.00k | -75.84m | 2.46bn | 61.00 | -- | 4.42 | -- | 3,780.05 | -1.17 | -1.17 | 0.01 | 8.29 | -- | -- | -- | 10,655.74 | -- | -- | -- | -- | -- | -- | -9,870.92 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
Structure Therapeutics Inc (ADR) | 0.00 | -100.44m | 2.46bn | 136.00 | -- | 2.67 | -- | -- | -2.24 | -2.24 | 0.00 | 16.10 | 0.00 | -- | -- | 0.00 | -17.07 | -- | -17.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
ACADIA Pharmaceuticals Inc | 890.53m | 30.57m | 2.50bn | 630.00 | 83.28 | 4.85 | 59.60 | 2.81 | 0.1813 | 0.1813 | 5.38 | 3.12 | 1.14 | 1.83 | 9.60 | 1,491,682.00 | 3.93 | -27.50 | 5.93 | -32.73 | 91.72 | 95.62 | 3.43 | -38.35 | 1.95 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
Veracyte Inc | 399.58m | -54.04m | 2.52bn | 815.00 | -- | 2.23 | -- | 6.31 | -0.7444 | -0.7444 | 5.37 | 14.76 | 0.3336 | 8.11 | 8.62 | 490,281.00 | -4.51 | -6.33 | -4.77 | -6.69 | 68.73 | 67.10 | -13.52 | -20.99 | 4.17 | -- | 0.00009 | -- | 21.76 | 31.45 | -103.51 | -- | 39.67 | -- |
Ideaya Biosciences Inc | 11.96m | -153.74m | 2.53bn | 124.00 | -- | 2.45 | -- | 211.70 | -2.18 | -2.18 | 0.1718 | 12.24 | 0.0159 | -- | 148.57 | 96,451.61 | -20.48 | -19.17 | -21.42 | -21.05 | -- | -- | -1,285.44 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
Geron Corp | 1.37m | -219.55m | 2.60bn | 141.00 | -- | 8.47 | -- | 1,896.63 | -0.3595 | -0.3595 | 0.0023 | 0.5103 | 0.0032 | -- | 0.6367 | 9,737.59 | -50.78 | -51.32 | -63.77 | -64.90 | 63.00 | -- | -15,990.60 | -19,949.13 | 3.60 | -- | 0.2139 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 11.07m | 14.94% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 6.35m | 8.57% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 4.87m | 6.57% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 4.03m | 5.44% |
Deep Track Capital LPas of 31 Mar 2024 | 3.48m | 4.70% |
Marshall Wace LLPas of 31 Mar 2024 | 2.97m | 4.00% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.96m | 4.00% |
Lord, Abbett & Co. LLCas of 31 Mar 2024 | 2.32m | 3.13% |
Perceptive Advisors LLCas of 31 Mar 2024 | 2.26m | 3.05% |
Maverick Capital Ltd.as of 31 Mar 2024 | 1.91m | 2.58% |